The results of fibrinolytic therapy with urokinase were evaluated in 26 neonates with catheter related central venous thrombosis. Complete thrombolysis could be achieved in 13 patients (50%), partial thrombo lysis in 3 patients (12%). No effect was seen in 10 patients (38%). Therapy success was influenced by age, size and location of the throm bus. Coincidence of infection occurred in 16 patients (62%), Mild hemorrhagic complications were seen in 2 patients (8%), no other significant side effects were observed, Nine patients with residual thrombosis were treated with oral anticoagulants following urokinase resulting in resolution of the thrombus in 6 patients within 3 months (67%). The incidence of asymptomatic recurrent thrombosis was high (28%). Urokinase might be an effective and safe treatment for central venous thrombosis in neonates. Prophylactic antibiotic therapy during the infusion of urokinase and long-term treatment with oral anticoagu lants after thrombosis are advisable, Early detection of thrombosis might enhance the success rate of fibrinolytic therapy. Therefore, we strongly recommend routine echocardiographic screening of central venous catheters.
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* introduction
The use of central venous catheters to optimize nutrition and moni toring of low birth weight and critically ill newborns has become com mon practice in neonatal intensive care units. However, these catheters are not without potential hazards. Sepsis and thrombosis are known ma jor complications (1) (2) (3) (4) . Central venous thrombosis can be associated with significant morbidity and mortality. Early detection and treatment is crucial.
There is no consensus in the literature about the treatment of choice for neonates with central venous thrombosis. Immediate removal of the catheter, once the diagnosis of central venous thrombosis is made, has been recommended (5) . However, the risk for pulmonary embolization due to mobilization of the thrombus is imaginable. Surgical thrombec tomy is technically difficult and poses a considerable life threatening risk to the severely ill infant (6) (7) (8) . Heparin is a prophylactic drug and could be used in patients with mild thrombosis to prevent further thrombus extension. Nevertheless, one should not rely exclusively on the endogenous fibrinolytic capacity of the neonate, but should attempt to lyse a major central venous thrombus with thrombolytic agents (9). In the past decade thrombolytic drugs have gained widespread recogni tion in the treatment of myocardial infarction, pulmonary embolism, deep venous and arterial thrombosis (10, 11) . Although used extensive ly in the adult, there is sparse information on their effectiveness in the newborn (6) . There have been no large case-series or controlled trials of infants treated with fibrinolytic agents for catheter related thrombosis. Eight case reports describe the use of urokinase in neonates, using dif ferent dosages and therapy durations (12) (13) (14) (15) (16) (17) (18) (19) . These initial successful reports regarding thrombolytic therapy in neonates encouraged us to apply this therapy to our patients. In this report, we present our experi ence of 26 infants treated with urokinase infusion for catheter related central venous thrombosis. Since September 1989 echo Doppler cardiography has been performed as routine screening in all patients with central venous catheters before removal of the catheter or sooner in case of symptoms of thrombosis. Before this data echo Doppler cardiography was only performed on indication. A thrombus was de fined as an echodense structure larger than 2 mm in the heart or in the great vessels. Special attention was paid to the superior and inferior vena cava, the hepatic vein and to malposition of the catheter in the left atrium. Length and diameter of the thrombus were measured in mm, thrombus mass was calculated in mm3 (^rr21, whereas r -radius and 1 = length of the thrombus). Echo Dopp ler cardiography led to the diagnosis in 23 patients (Fig. 1) . Some peripheral veins (subclavian vein, hepatic vein) are easier visualized by catheter phle bography, which was used in 3 patients to confirm the diagnosis. For all data, means and standard deviations were calculated. Statistical ana lysis was performed where necessary using the Chi-square test, Wilcoxon test or Student-t-test. Results were considered to be significant when p <0.05.
Patients and Methods
Between
Results
Characteristics of 26 neonates with central venous thrombosis are presented in Table 1 . The remaining 408 patients without central ve nous thrombosis had a mean birth weight of 1988 ± 1041 grams and a mean gestational age of 33.5 ±5.0 weeks. Both birth weight and gesta tional age were significantly higher in the group with thrombosis (p <0.05 and p <0.02).
Among the 26 patients with catheter related central venous throm bosis prematurity (n = 8) and birth asphyxia (n = 7) were the main rea sons for admission to our department. Less frequent diagnoses were congenital diaphragmatic hernia (n = 3), meconium aspiration syn drome (n = 2), sepsis (n = 2), gastro-intestinal surgery (n = 2), pneumo thorax (n = 1) and chylothorax (n = 1). All patients were critically ill on admission, 24 required artificial ventilation, All patients received total Half of the central venous catheters were inserted within the first two days of life. Umbilical vein catheterization was performed in 14 pa tients. The percutaneous method via peripheral veins was applied in 4 patients. In 5 patients venous access was achieved by means of percutaneous catheterization of the subclavian vein and in 3 patients by means of cutdown of the jugular vein. Catheters used were Polyvinylchloride umbilical catheters 5 French (n = 5), hydrophilic polyurethane umbilical catheters 5 French (n = 7), single lumen hydro philic percutaneous catheters 22 or 20 Gauge (n = 7), double lumen hydrophilic polyurethane percutaneous catheters 18 Gauge (n = 3), and silastic catheters 4.2 French (n = 3). In one patient the type of the catheter was unknown.
At the time of diagnosis 15 patients (58%) had clinical symptoms suspicious for central venous thrombosis, particularly sepsis (n = 14), sometimes in combination with superior or inferior vena cava syn drome (n = 8) and/or chylothorax (n = 1). The remaining 11 patients (42%) had no clinical symptoms of thrombosis at the time of diagnosis, except signs of catheter malfunction such as partial or complete occlu sion (n = 2). Positive blood or catheter tip cultures were found in 16 patients (62%). Eleven of these patients also had clinical signs of sepsis. The in fections were predominantly caused by Staphylococcus epidermidis (n = 9). Other cultured micro-organisms included: Staphylococcus aureus (n = 2); Escherichia coli (n = 2); Enterobacter cloacae (n = 2); Klebsiella oxytoca (n = 1). The occurrence of infection seemed to be in fluenced by the indwelling time of the catheter: a mean indwelling time of 15 days in patients with infection, and a mean indwelling time of 10 days in patients without infection. The difference was not statisti cally significant.
In 10 patients the thrombus was located in the right atrium (38%). Other locations included: superior vena cava (n = 5); inferior vena cava (n = 2); left atrium (n = 3); hepatic vein (n = 4); subclavian vein (n = 2). Thrombosis in the left atrium could be explained by malposition of the central venous catheter with crossing of the foramen ovale. Mean thrombus size at the time of diagnosis was 263 mm3.
Coagulation studies before therapy and average urokinase dosage are listed in Table 1 > Average thrombin time and fibrinogen course dur ing urokinase therapy are mapped out in Fig. 2 . In 19 patients a throm bin time >50 s was achieved. In 9 patients fibrinogen dropped below 1000 mg/1 and fresh frozen plasma was administered during urokinase infusion. Neither the maximum thrombin time nor the administration of fresh frozen plasma correlated with therapy success.
Complete thrombolysis was achieved in 13 patients (50%). In these patients there was no residual thrombus detectable by echo Dopier car diography after urokinase therapy, indicating a thrombus mass reduc tion of 100%. Partial thrombolysis could be achieved in 3 patients (12%). These patients presented a reduction in thrombus mass of 64%, 61% and 20% respectively. Of the remaining 10 patients (38%) the thrombus did not change or became even larger despite urokinase thera py. Hence, therapy failure was observed in a total of 13 patients (50%). In one patient an extremely large thrombus extended through the for amen ovale into the left atrium, necessitating surgical thrombectomy to prevent cerebral thromboembolic complications. Several factors influencing therapy success of urokinase are presented in Table 2 * Mild hemorrhagic complications were noted in 2 patients. In these cases therapy was stopped because of persistent oozing from previous heel puncture sites and a dropping hemoglobin level. Both patients had a fibrinogen level below 1000 mg/1 before the onset of hemorrhagic complications. The remaining 7 patients with fibrinogen levels below 1000 mg/1 (lowest value 215 mg/1) did not have any signs of bleeding. Cerebral hemorrhage or focal ischemic cerebral damage due to embolic complications were excluded in our patients by means of ultrasound examination. especially silastic catheters has been reported by several authors (2, 16, 23) . The incidence of central venous thrombosis in our department was 6%. Due to the lack of routine screening of central venous catheters during the first year of our study period, and the fact that catheter phlebography was not performed systematically in our patients an underestimation of the incidence of thrombosis may be possible. Thrombosis on the tip of a central venous catheter can cause obOf 12 patients with residual thrombosis 9 received additional struction and catheter malfunction and subsequent stasis of blood and treatment with oral anticoagulants (Fig. 3) . In six of these patients the solutions (13) . Superimposed infection with bacteria or fungi easily treated residual clots resolved within 3 months* Two patients with occurs and can lead to life-threatening illness (22, 24) . Right atrial residual thrombosis died of severe bronchopulmonary dysplasia and thrombi may obstruct venous return which can lead to superior or infesepsis before oral medication was tolerated, and in one patient a rior vena cava syndrome, hydrocephalus, or chylothorax (22, 25, 26) . contraindication for oral anticoagulants was present. Of 14 patients When the thrombus extends through the tricuspid valve into the right without residual thrombosis after urokinase therapy or thrombectomy ventricle tricuspid insufficiency may incite cardiac failure (12, 27) . If 7 received oral anticoagulants. At follow-up ultrasound asymptomatic clot disruption occurs, irreversible vascular obstructive disease may re recurrent thromboses were noted in 4 of 14 successfully treated pa-suit from multiple small micro-emboli in the pulmonary vasculature. tients, 3 despite additional oral anticoagulants.
Discussion
Cardiac arrest and death due to major pulmonary embolism have been reported (16, 22, 27) . Cerebral emboli are also possible in cases of left atrial thrombi (27) . We noted several of these complications in our patients, particularly infection and vena cava syndrome. Nevertheless, Central venous thrombosis has been reported to occur in 2-10% as much as 35% of our patients remained asymptomatic. of neonates with central venous catheters (3, 4,13, 22 ). An increased Prevention of these harmful complications by early detection of incidence of thrombosis (up to 25%) with the use of larger catheters, thrombosis is essential. Echo Doppler cardiography or catheter phle-bography are most frequently applied for this purpose. Echo Doppler cardiography allows visualization and accurate localization and meas urement of a thrombus in the heart or great vessels. Modern ultrasound technology makes it possible to distinguish distances of less than 1 mm (28). However, in neonates the diagnostic efficacy of echocardiography for the detection of venous thrombosis has not been adequately as sessed (29) . Also, echo Doppler cardiography can not provide sufficient assessment to thrombosis in peripheral veins. Therefore, studies com paring echo Doppler cardiography and catheter phlebography in neo nates are urgently needed. The importance of routine screening for throm bosis has been emphasized in the literature. It has been recommended that the initial investigation should be obtained no sooner than 3 weeks after catheter insertion (3). Nevertheless, in our study 19 (73%) throm bi were detected at a catheter indwelling time of less than 14 days, in dicating that the initial screen should be obtained before the second week.
significant differences can not be proved. Rather large differences are required to obtain statistical significance. Nevertheless, these results could provide some guidelines for future investigations in neonates. Perinatal asphyxia and sepsis are thought to be risk factors for the development of thrombosis, possibly related to some degree of dis seminated intravascular coagulation and hypoxic damage to vessel endothelium (6, 37, 38) . We noted a high incidence of infection in our patients (62%). Therefore, we recommend prescribing antibiotics in neonates with thrombosis in an attempt to treat coexistent or prevent superimposed infection and possibly therapy failure. Because of the predominance of gram-positive strains (69%) small-spectrum anti biotics may be applied, unless blood cultures prove otherwise. Broadspectrum antibiotics should only be given if necessary, because of the risk of roultiresistant strains.
A significantly higher birth weight and gestational age were found in neonates with catheter related central venous thrombosis when comIn our opinion, of the conventional thrombolytic agents urokinase is pared to neonates without thrombosis in the presence of a central the drug of choice in the neonatal period because of its single-step plas-venous catheter. These findings suggest that neonates with a higher minogen activation, a more predictable dose-response relationship than birthweight and gestational age are at risk for developing catheter other agents and its nonantigenicity in humans (6, 10) . Streptokinase related central venous thrombosis. A relatively large proportion of should not be used in the newborn because of risk of bleeding compli-neonates with a higher weight probably has perinatal asphyxia or cations during prolonged use. Urokinase has a more selective action on sepsis, which may contribute to the development of thrombosis. Anfibrin, and is therefore less dangerous. Recently developed thrombo-other possibility is that small thrombi may be overlooked in low birth lytic agents such as recombinant single-chain urokinase plasminogen weight neonates because of the difficulty of performing echo Doppler activator (r scu-PA) and recombinant tissue-type plasminogen activator cardiography, which therefore becomes less reliable in these infants. (rt-PA) could also be applied in the newborn, however experience with Hemorrhagic complications during thrombolytic therapy occur in these agents in neonates is limited (29) (30) (31) . Moreover, a recent mul-about 5% of adult patients (29, 30) . In neonates, hemorrhagic and ticenter trial in adults has reported a higher incidence of cerebral embolic complications are especially feared. In case reports using urohaemorrhage with the use of rt-PA (32) .
kinase for central venous thrombosis in neonates pulmonary embolism In studies performed on adults the incidence of reperfusion of coro-has been reported in 2 of 29 neonates (7%) (14, 16) . Cereberal hemornary arteries has been 60-70%, regardless of the agent used (29, 30) . In adults with catheter related central venous thrombosis, treatment with urokinase resulted in complete thrombolysis in 36 of 38 patients (95%) (8%).
rhage has been reported once in a patient with arterial thrombosis (39) . We noted only mild peripheral hemorrhagic complications in 2 patients (33) . In the literature, 8 case reports describe the use of urokinase in
In adults, approximately 10 to 20 percent of reperfused arteries newborns, resulting in thrombolysis in 26 of 29 infants (90%) (12) (13) (14) (15) (16) (17) (18) (19) . develop recurrent thrombosis despite additional anticoagulant therapy In contrast, we could only achieve complete thrombolysis in 50% of our (29, 30) . In the neonatal case-reports reviewed by these authors re patients, in spite of high dosages of urokinase, It seems likely that in current thrombosis occurred in 6 of 29 patients (21%) (12) (13) (14) (15) (16) (17) (18) (19) . In our neonates the results of thrombolytic therapy are less favourable than in study 4 patients developed recurrent thrombosis (28%), three despite adults. Factors such as reduced levels of plasminogen, and higher levels of inhibitors of plasminogen activation have been thought to contribute to a decreased fibrinolytic activity in the newborn and an impaired re anticoagulant therapy. Of 9 residual thrombi after urokinase therapy 6 (67%) resolved following additional anticoagulant therapy for 3 months, It is not clear whether these thrombi would have resolved sponse to fibrinolytic therapy in newborns compared to adults (34) (35) (36) . spontaneously without anticoagulant therapy. Patients with and without Investigators have suggested that the newborn may need up to 11 times residual thrombosis after urokinase therapy may benefit from addithe usual dosage of urokinase compared to adults (9) . A recent in vitro study showed an evident resistance of newborn fibrin clots to all throm bolytic agents due to low levels of plasminogen. The degree of fibrino lysis could be increased to adult values by increasing plasminogen con centrations (35) . These findings may explain the relative insensitivity to even high dosages of thrombolytic agents in newborn, which is also tionai treatment with oral anticoagulants. The appropriate duration and dose of oral anticoagulants needs further investigation, Prevention of catheter related central venous thrombosis is an im portant, yet unresolved, issue, A continuous infusion of low dose hepa rin has been shown to prolong catheter patency (40) , but a significant reduction in catheter related central venous thrombosis has not been illustrated by the minimal alterations in thrombin time and fibrinogen confirmed (8, 41) . Despite heparin prophylaxis in all patients with cenIevel during urokinase therapy (Fig. 2) . It is possible that increasing the tral venous catheters we reported a rather high incidence of thrombosis concentration of plasminogen will enhance the clinical response to (6%). Hydrophilic polyurethane catheters seem to have the least thromthrombolytic therapy in newborns. However, in our patients the ad ministration of fresh frozen plasma did not enhance the success rate of urokinase therapy. bogenic properties (42) . However, prolonged use of hydrophilic poly urethane catheters did not lead to a significant reduction in the inci dence of thrombi when compared to prolonged use of polyvinyl Other factors that are less favourable for successful thrombolytic chloride catheters (43) . It is possible that the abnormal coagulation and therapy are peripheral location of the thrombus, large thrombus size, fibrinolytic system in the newborn and conditions such as sepsis and thrombus age more than 7 days and low plasminogen concentration (10) . We noted that a lower incidence of successful thrombolysis in our asphyxia are of greater importance in the etiology of catheter related thrombosis. Apart from limited use of central venous catheters, patients may have been related to some of these factors (Table 2 ), but especially in asphyxiated and septic newborns, ealry detection and appropriate treatment of catheter related central venous thrombosis remain of crucial importance.
